Search

Displaying results 7361 - 7370 of 10000 in total
  1. Drug

    Bersanlimab

    go.drugbank.com/drugs/DB17377
    Investigational

    Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).

  2. Drug

    Trinitrotoluene

    go.drugbank.com/drugs/DB01676
    Experimental

    Trinitrotoluene is an explosive chemical that can cause skin irritation and other toxic consequences.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Arotinoid acid

    go.drugbank.com/drugs/DB02877
    Experimental

    Arotinoid acid is a retinoic acid analog which acts as a selective RAR agonist.

  4. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  5. Drug

    XC221

    go.drugbank.com/drugs/DB16503
    Investigational

    XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

  6. Drug

    Relacatib

    go.drugbank.com/drugs/DB06367
    Investigational

  7. Drug

    Cathine

    go.drugbank.com/drugs/DB01486
    ExperimentalIllicit

    Cathine, also known as d-norpseudoephedrine and (+)-norpseudoephedrine, is a psychoactive drug with stimulant properties. It belongs to the phenethylamine and amphetamine chemical classes. … In the United States, it is classified as a Schedule IV controlled substance.

    Synonyms: D-Cathine, d-Nor-psi-ephedrine
  8. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

  9. Drug

    AZX-100

    go.drugbank.com/drugs/DB06323
    Investigational

  10. Drug

    XmAb24306

    go.drugbank.com/drugs/DB17526
    Investigational

    XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.